Two separate teal component forms in a grouped arrangement.

Our evidence assessments are specific to a combination, outcome, population, and formulation.

Read our grading method

Semaglutide + cagrilintide / CagriSema

Semaglutide + Cagrilintide

Semaglutide + cagrilintide / CagriSema: ingredient studies, complete-combination evidence gaps, dose, route and safety questions in the available research.

Peptide stack
Primary investigators

Recorded source check: 4 October 2026

Review and updates

Overview

This guide covers Semaglutide + Cagrilintide, also known here as CagriSema, and links research records concerning the combination. The primary PDF collection provides study-specific methods and observations, which need to be assessed against the preparation, population, comparator, and outcomes actually tested. An outcome-specific assessment of those records has not yet been completed on this page. The guide keeps direct combination research separate from ingredient studies and does not infer that every commercial mixture matches the formulation described in a paper.

Ingredients

The combination examined on this page contains Semaglutide + Cagrilintide. Each ingredient needs to be identified by its actual molecule and preparation before research can be matched to the combination. The linked ingredient guides provide a route into that evidence, while ingredients without a dedicated guide remain named explicitly. A shared nickname, similar product label, or premixed presentation cannot establish that every ingredient, concentration, and route matches a published intervention.

Why combine them?

The reason to investigate Semaglutide + Cagrilintide together must be separated from the results of testing that combination. The linked combination records provide a starting point for examining whether adding an ingredient changes the measured outcome relative to an appropriate comparator. This guide has not yet completed that comparison or assigned an outcome-specific evidence grade. Any conclusion about an added benefit must preserve the tested formulation, population, treatment period, and adverse-event findings rather than rely on the ingredients’ proposed roles alone.

Combination benefits

No effectiveness assessment for the complete Semaglutide + Cagrilintide combination has been established from the primary sources attached to this guide. A positive finding for one ingredient cannot determine the size or direction of an effect when other ingredients are added. Claims about improved recovery, symptoms, body composition, or another outcome must be evaluated against what a combination study actually measured. Until that direct assessment is available, the ingredient evidence remains background and the added-benefit question remains unresolved.

Safety & interactions

This page does not establish the safety or interaction profile of Semaglutide + Cagrilintide taken together. Assessing that question requires the full formulation, route, exposure, concurrent treatments, and adverse-event reporting from relevant combination research. Tolerability observed with an ingredient alone cannot establish the safety of adding the other ingredients, and missing reports cannot be treated as reassurance. Any proposed clinical use also requires an assessment of the individual’s circumstances rather than a conclusion drawn solely from a stack name.

Read the Medical Disclaimer.

Forms & dosing

The combination study records linked here contain source-specific information relevant to Semaglutide + Cagrilintide, but this guide does not provide a general dosing or mixing protocol. Reported amounts must remain attached to the tested preparation, route, schedule, population, and monitoring arrangements. Separate ingredient schedules should not be combined to construct a new regimen, and a trial preparation should not be assumed equivalent to a commercial mixture. The record details support interpretation of the research while a formulation-specific clinical assessment remains incomplete.

Evidence

These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.

Complete-combination evidence has not yet been assessed for this guide.

Research Feed

Studies

Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.

Scope identifies studies of this combination and studies of its individual ingredients. Ingredient studies do not establish the benefits or safety of the combination.

CombinationPDF recordCagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure
CombinationPDF recordEfficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1
CombinationPDF recordCagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1
IngredientPDF recordArtificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis
IngredientPDF recordBimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
IngredientPDF recordComparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study
IngredientPDF recordComparative effectiveness of sleeve gastrectomy and semaglutide for weight loss and metabolic outcomes: a prospective non‑randomized study
IngredientPDF recordDose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP‑1 receptor agonist, compared with placebo and open‑label semaglutide in people with type 2 diabetes: a randomised clinical trial
IngredientPDF recordEffect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis
IngredientPDF recordEffect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial
IngredientPDF recordEffects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
IngredientPDF recordEfficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
IngredientPDF recordEfficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE
IngredientPDF recordEfficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus
IngredientPDF recordEfficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
IngredientPDF recordEfficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial
IngredientPDF recordEfficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials
IngredientPDF recordEfficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials
IngredientPDF recordEfficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double‑blind, Phase IIIa, randomised trial
IngredientPDF recordEfficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double‑blind, Phase IIIa, randomised trial
IngredientPDF recordExploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH
IngredientPDF recordHigh-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial
IngredientPDF recordImpact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach
IngredientPDF recordImproved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial
IngredientPDF recordIndirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes
IngredientPDF recordInsulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)—An International Phase 3 Clinical Trial
IngredientPDF recordLong-acting PYY336 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies
IngredientPDF recordLong-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial
IngredientPDF recordLong-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
IngredientPDF recordOnce‑weekly IcoSema versus once‑weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial
IngredientPDF recordOnce-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase IIb single-centred clinical trial
IngredientPDF recordOral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
IngredientPDF recordOral semaglutide for Alcohol Use Disorder: A randomized clinical trial
IngredientPDF recordPharmacokinetics, Safety and Tolerability of Once- Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
IngredientPDF recordSafety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
IngredientPDF recordSafety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
IngredientPDF recordSemaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly
IngredientPDF recordSemaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study
IngredientPDF recordSemaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study
IngredientPDF recordSemaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials
IngredientPDF recordSemaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity
IngredientPDF recordOnce-Weekly Semaglutide in Adults with Overweight or Obesity
IngredientPDF recordSemaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
IngredientPDF recordWeight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
IngredientPDF recordevoke and evoke+: design of two largescale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
IngredientPDF recordSemaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
IngredientPDF recordTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
IngredientPDF recordLong-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
IngredientPDF recordLong-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
IngredientPDF recordEffects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
IngredientPDF recordRandomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging
IngredientPDF recordEffects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
IngredientPDF recordSemaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
IngredientPDF recordThe effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
IngredientPDF recordGastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
IngredientPDF recordMitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro
IngredientPDF recordRenal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide
IngredientPDF recordCagrilintide lowers bodyweight through brain amylin receptors 1 and 3
IngredientPDF recordEloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
IngredientPDF recordStructural and dynamic features of cagrilintide binding to calcitonin and amylin receptors
IngredientPDF recordA cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance
IngredientPDF recordDistinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism
IngredientPDF recordSafety and Tolerability of Concomitant Administration of Multiple-Dose AM833 With Semaglutide 2.4 MG for Weight Management
IngredientPDF recordPreclinical Weight Loss Efficacy of AM833 in Combination With Semaglutide in Rodent Models of Obesity

FAQs

Do the ingredient studies prove that the complete stack works?
Quick answer:

No effectiveness assessment for the complete Semaglutide + Cagrilintide combination has been established from the primary sources attached to this guide. A positive finding for one ingredient cannot determine the size or direction of an effect when other ingredients are added. Claims about improved recovery, symptoms, body composition, or another outcome must be evaluated against what a combination study actually measured. Until that direct assessment is available, the ingredient evidence remains background and the added-benefit question remains unresolved.

Can separate study doses be combined into a stack protocol?
Quick answer:

The combination study records linked here contain source-specific information relevant to Semaglutide + Cagrilintide, but this guide does not provide a general dosing or mixing protocol. Reported amounts must remain attached to the tested preparation, route, schedule, population, and monitoring arrangements. Separate ingredient schedules should not be combined to construct a new regimen, and a trial preparation should not be assumed equivalent to a commercial mixture. The record details support interpretation of the research while a formulation-specific clinical assessment remains incomplete.

Update History

Evidence and review status

Recorded source check
Subsequent substantive evidence update
No later update is recorded for Semaglutide + cagrilintide / CagriSema.
Independent clinical review
Pending; this selected-source guide is AI-assisted.

A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.

Read the editorial method

References

0 sources

This page does not yet have an assessed reference supporting a clinical conclusion about the complete topic. Ingredient links and the broader source library can help locate relevant research, but a related paper is not automatically evidence for the intervention named here. Any future citation needs to be matched to its actual population, formulation, comparison, and outcome. The absence of a reference on this page describes the present review and should not be interpreted as a literature-wide absence of research.